EcoDrugPlus

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSATEG00000014673
Gene Symbol: TOP2A
2 Cross references
205 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSATEG00000008292
Gene Symbol: TOP2B
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSATEG00000015061
Gene Symbol: TOP1A
1 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSATEG00000022754
Gene Symbol: LOC113159394
2 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSATEG00000001256
Gene Symbol: EPHA3
3 Cross references
211 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSATEG00000010348
Gene Symbol: FYNA
4 Cross references
192 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSATEG00000012659
Gene Symbol: FYNB
4 Cross references
196 Possible Orthologues:

G1/s-Specific Cyclin-D1-Like

Ensembl ID : ENSATEG00000004455
Gene Symbol: LOC113165234
2 Cross references
205 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSATEG00000000402
Gene Symbol: HCK
3 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSATEG00000000704
Gene Symbol: ITK
3 Cross references
208 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSATEG00000018624
Gene Symbol: IMPDH1B
2 Cross references
258 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSATEG00000007063
Gene Symbol: IMPDH2
4 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).